1415113-22-2Relevant academic research and scientific papers
2 - (5,6-dimethyl-xanthone-4-yl)-acetic acid derivatives, process for preparation thereof and use
-
Paragraph 0079-0081; 0090; 0091, (2016/10/10)
The present invention provides a class of 2-(5,6-methylxanthone-4-yl)-acetic acid derivatives with a novel structure, wherein a structure of a general formula is represented by a picture. The present invention further provides a method for preparing the derivatives, wherein multiple structure modification reforming are performed on a carboxyl portion of 2-(5,6-methylxanthone-4-yl)-acetic acid to prepare the derivatives. Compared with the existing 2-(5,6-methylxanthone-4-yl)-acetic acid or derivatives thereof, a part of the derivatives prepared by using the method of the present invention provide inhibition effects for a variety of tumor cells, particularly provide high tumor cell inhibition rate for lung cancer and leukemia, and show significant anti-tumor activities. According to the present invention, the design is rational, sources of the raw materials for preparation are wide, the raw materials are easy to obtain, the preparation method is simple and easy to operate, reaction conditions are mild, the product yield is high, and the method is applicable for industrial large scale production.
Synthesis, anticancer evaluation and docking study of vadimezan derivatives with carboxyl substitution
Zhang, Shi-Jie,Ding, Zhi-Shan,Jiang, Fu-Sheng,Ge, Qiu-Fu,Guo, Dian-Wu,Li, Hai-Bo,Hu, Wei-Xiao
supporting information, p. 512 - 520 (2014/04/17)
A series of xanthone analogues modified from vadimezan 6 with carboxyl substitution were synthesized as esters, amides, arylidene hydrazides, diacylhydrazides and acyl thiosemicarbazides, and their structures were confirmed by IR, 1H NMR, MS, HRMS or elemental analysis. The in vitro anticancer activities were evaluated by the MTT method. It was found that compounds 8f, 8g and 10e were effective against A549 with an IC50 at 10.8 μM, 9.4 μM and 11.5 μM respectively, and that 8e was effective against HL-60 with an IC50 at 4.6 μM. Compounds 8f-h showed a significant inhibitory effect on HUVEC growth and migration in vitro, among which 8h inhibited HUVEC growth with an IC50 at 6.4 μM and HUVEC migration by 67.6% and 89.7% at 2.5 μg mL-1 and 10 μg mL -1 respectively. More spectacularly, docking study indicated that compound 8h might target the ATP binding site of VEGFR2. In addition, compounds 8a, 8f-h exhibited moderate in vivo antitumor efficacy against the S180 xenograft in ICR mice by 22.4-29.6% tumor weight inhibition.
